Lisa Price - Deciphera Pharmaceuticals Senior Officer
| DCPH Stock | USD 25.55 0.03 0.12% |
Executive
Lisa Price is Senior Officer of Deciphera Pharmaceuticals LLC
| Address | 200 Smith Street, Waltham, MA, United States, 02451 |
| Phone | 781 209 6400 |
| Web | https://www.deciphera.com |
Deciphera Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2662) % which means that it has lost $0.2662 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5037) %, meaning that it created substantial loss on money invested by shareholders. Deciphera Pharmaceuticals' management efficiency ratios could be used to measure how well Deciphera Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.43. The current Return On Capital Employed is estimated to decrease to -0.59. As of now, Deciphera Pharmaceuticals' Fixed Asset Turnover is increasing as compared to previous years. The Deciphera Pharmaceuticals' current Asset Turnover is estimated to increase to 0.36, while Total Assets are projected to decrease to under 393.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nyree Pinto | Tilray Inc | N/A | |
| Nick Ashton | Zoetis Inc | 51 | |
| Ester Banque | Zoetis Inc | 54 | |
| Steven Frank | Zoetis Inc | N/A | |
| Jeannette Astorga | Zoetis Inc | 49 | |
| Roger Savell | Tilray Inc | 62 | |
| William Dorsey | Zoetis Inc | N/A | |
| Ed Petter | Haleon plc | N/A | |
| Lisa Evoli | Catalent | 54 | |
| Amanda Morgan | Lantheus Holdings | N/A | |
| Randy Daigneau | Tilray Inc | N/A | |
| Jamie Brannan | Zoetis Inc | 51 | |
| Daniel Niedzwiecki | Lantheus Holdings | 46 | |
| John Sadler | Tilray Inc | N/A | |
| Mitchell Gendel | Tilray Inc | 58 | |
| Rimma Driscoll | Zoetis Inc | 50 | |
| Franck Riot | Haleon plc | 56 | |
| John MBA | Catalent | 69 | |
| Berrin Noorata | Tilray Inc | N/A | |
| Namrata Patel | Haleon plc | 58 | |
| Dorothy Barr | Lantheus Holdings | N/A | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 |
Deciphera Pharmaceuticals Leadership Team
Elected by the shareholders, the Deciphera Pharmaceuticals' board of directors comprises two types of representatives: Deciphera Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Deciphera. The board's role is to monitor Deciphera Pharmaceuticals' management team and ensure that shareholders' interests are well served. Deciphera Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Deciphera Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel Flynn, Founder, Chief Scientific Officer | ||
| Daniel Martin, Chief Commercial Officer | ||
| Margarida Duarte, Senior International | ||
| Stephen Ruddy, VP Officer | ||
| Kevin Brodbeck, Senior Officer | ||
| Lisa Price, Senior Officer | ||
| Matthew MD, Executive Officer | ||
| Jeffrey JD, Senior Counsel | ||
| Steven Hoerter, President CEO | ||
| Dashyant Dhanak, Executive Officer | ||
| Thomas JD, CFO VP | ||
| Jennifer Larson, Senior Relations | ||
| Jama Pitman, Quality Regulatory |
Deciphera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Deciphera Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (1.09) % | ||||
| Operating Margin | (1.09) % | ||||
| Current Valuation | 1.96 B | ||||
| Shares Outstanding | 86.48 M | ||||
| Shares Owned By Insiders | 28.48 % | ||||
| Shares Owned By Institutions | 72.06 % | ||||
| Number Of Shares Shorted | 3.92 M | ||||
| Price To Earning | (6.78) X |
Currently Active Assets on Macroaxis
| VTSNX | Vanguard Total International | |
| VBTIX | Vanguard Total Bond | |
| VMCIX | Vanguard Mid Cap Index | |
| GOOGL | Alphabet Inc Class A | |
| AMZN | Amazon Inc |
Additional Information and Resources on Investing in Deciphera Stock
When determining whether Deciphera Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Deciphera Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Deciphera Pharmaceuticals Llc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Deciphera Pharmaceuticals Llc Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Deciphera Pharmaceuticals LLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Deciphera Pharmaceuticals. If investors know Deciphera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Deciphera Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.21) | Revenue Per Share 2.028 | Quarterly Revenue Growth 0.345 | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Deciphera Pharmaceuticals is measured differently than its book value, which is the value of Deciphera that is recorded on the company's balance sheet. Investors also form their own opinion of Deciphera Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Deciphera Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Deciphera Pharmaceuticals' market value can be influenced by many factors that don't directly affect Deciphera Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Deciphera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Deciphera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Deciphera Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.